Literature DB >> 20549313

Clinical developments in nanotechnology for cancer therapy.

Jeremy D Heidel1, Mark E Davis.   

Abstract

Nanoparticle approaches to drug delivery for cancer offer exciting and potentially "game-changing" ways to improve patient care and quality of life in numerous ways, such as reducing off-target toxicities by more selectively directing drug molecules to intracellular targets of cancer cells. Here, we focus on technologies being investigated clinically and discuss numerous types of therapeutic molecules that have been incorporated within nanostructured entities such as nanoparticles. The impacts of nanostructured therapeutics on efficacy and safety, including parameters like pharmacokinetics and biodistribution, are described for several drug molecules. Additionally, we discuss recent advances in the understanding of ligand-based targeting of nanoparticles, such as on receptor avidity and selectivity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20549313     DOI: 10.1007/s11095-010-0178-7

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  118 in total

1.  PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2.

Authors:  Kathy S Albain; Chandra P Belani; Philip Bonomi; Kenneth J O'Byrne; Joan H Schiller; Mark Socinski
Journal:  Clin Lung Cancer       Date:  2006-05       Impact factor: 4.785

2.  Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes.

Authors:  E T Dams; P Laverman; W J Oyen; G Storm; G L Scherphof; J W van Der Meer; F H Corstens; O C Boerman
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

3.  Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

Authors:  Nuhad K Ibrahim; Neil Desai; Sewa Legha; Patrick Soon-Shiong; Richard L Theriault; Edgardo Rivera; Bita Esmaeli; Sigrid E Ring; Agop Bedikian; Gabriel N Hortobagyi; Julie A Ellerhorst
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

4.  Relationships between the structure of taxol analogues and their antimitotic activity.

Authors:  F Guéritte-Voegelein; D Guénard; F Lavelle; M T Le Goff; L Mangatal; P Potier
Journal:  J Med Chem       Date:  1991-03       Impact factor: 7.446

Review 5.  Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability.

Authors:  Daniele Venturoli; Bengt Rippe
Journal:  Am J Physiol Renal Physiol       Date:  2005-04

6.  Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance.

Authors:  C Cuvier; L Roblot-Treupel; J M Millot; G Lizard; S Chevillard; M Manfait; P Couvreur; M F Poupon
Journal:  Biochem Pharmacol       Date:  1992-08-04       Impact factor: 5.858

7.  Development and characterization of a novel liposome-based formulation of SN-38.

Authors:  J Allen Zhang; Tong Xuan; Manjeet Parmar; Lan Ma; Sydney Ugwu; Shahid Ali; Imran Ahmad
Journal:  Int J Pharm       Date:  2004-02-11       Impact factor: 5.875

8.  Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.

Authors:  J C Panetta; A Gajjar; N Hijiya; L J Hak; C Cheng; W Liu; C H Pui; M V Relling
Journal:  Clin Pharmacol Ther       Date:  2009-09-09       Impact factor: 6.875

Review 9.  Nanoparticle therapeutics: an emerging treatment modality for cancer.

Authors:  Mark E Davis; Zhuo Georgia Chen; Dong M Shin
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

Review 10.  Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate.

Authors:  Stewart D Chipman; Fred B Oldham; Gabriella Pezzoni; Jack W Singer
Journal:  Int J Nanomedicine       Date:  2006
View more
  47 in total

1.  Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents.

Authors:  Jonathan F Lovell; Cheng S Jin; Elizabeth Huynh; Honglin Jin; Chulhong Kim; John L Rubinstein; Warren C W Chan; Weiguo Cao; Lihong V Wang; Gang Zheng
Journal:  Nat Mater       Date:  2011-03-20       Impact factor: 43.841

Review 2.  Strategies to target tumors using nanodelivery systems based on biodegradable polymers, aspects of intellectual property, and market.

Authors:  Michele F Oliveira; Pedro P G Guimarães; Alinne D M Gomes; Diego Suárez; Rubén D Sinisterra
Journal:  J Chem Biol       Date:  2012-11-30

Review 3.  Advances in nanotechnology and asthma.

Authors:  Lingwei Wang; Mengjie Feng; Qiuwen Li; Chen Qiu; Rongchang Chen
Journal:  Ann Transl Med       Date:  2019-04

4.  Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy.

Authors:  Mithun M Shenoi; Isabelle Iltis; Jeunghwan Choi; Nathan A Koonce; Gregory J Metzger; Robert J Griffin; John C Bischof
Journal:  Mol Pharm       Date:  2013-04-17       Impact factor: 4.939

5.  Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis.

Authors:  Horacio Cabral; Mami Murakami; Hironori Hojo; Yasuko Terada; Mitsunobu R Kano; Ung-il Chung; Nobuhiro Nishiyama; Kazunori Kataoka
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-25       Impact factor: 11.205

6.  EFFECTS OF POLYMERIC NANOPARTICLE SURFACE PROPERTIES ON INTERACTION WITH BRAIN TUMOR ENVIRONMENT.

Authors:  Brandon Mattix; Thomas Moore; Olga Uvarov; Samuel Pollard; Lauren O'Donnell; Katelyn Park; Devante Horne; Jhilmil Dhulekar; Laura Reese; Duong Nguyen; Jacqueline Kraveka; Karen Burg; Frank Alexis
Journal:  Nano Life       Date:  2013-12-17

7.  Remote loading of preencapsulated drugs into stealth liposomes.

Authors:  Surojit Sur; Anja C Fries; Kenneth W Kinzler; Shibin Zhou; Bert Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-28       Impact factor: 11.205

8.  Targeted PRINT Hydrogels: The Role of Nanoparticle Size and Ligand Density on Cell Association, Biodistribution, and Tumor Accumulation.

Authors:  Kevin G Reuter; Jillian L Perry; Dongwook Kim; J Christopher Luft; Rihe Liu; Joseph M DeSimone
Journal:  Nano Lett       Date:  2015-09-30       Impact factor: 11.189

9.  Micelle Delivery of Parthenolide to Acute Myeloid Leukemia Cells.

Authors:  Michael P Baranello; Louisa Bauer; Craig T Jordan; Danielle S W Benoit
Journal:  Cell Mol Bioeng       Date:  2015-04-25       Impact factor: 2.321

Review 10.  Update on current and potential nanoparticle cancer therapies.

Authors:  Jonathan S Rink; Michael P Plebanek; Sushant Tripathy; C Shad Thaxton
Journal:  Curr Opin Oncol       Date:  2013-11       Impact factor: 3.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.